Skip to main content

Advertisement

SpringerLink
Log in

What Is the Role of Nutrition Therapy in the Management of the Adult Cystic Fibrosis Patient?

  • Gastroenterology and Nutrition (SA McClave, Section Editor)
  • Published:
Current Nutrition Reports Aims and scope Submit manuscript

Abstract

Once a death sentence, many patients with cystic fibrosis (CF) are now surviving into their forties and almost half of the current CF population in the USA are over the age of 18 years. Nutritional interventions that are aimed towards maintaining normal weight and prevention of nutritional deficiencies are critical in the management of CF and directly impact pulmonary function and survival. CF is a multisystem disease and several complications can interfere with the ability to ingest food or digest and absorb nutrients. This review investigates various gastrointestinal and endocrine complications that impact nutritional status in CF. Specific nutritional therapies are highlighted ranging from nutritional counseling to enteral and parenteral nutrition with emphasis on pancreatic enzyme replacement therapy and the challenges associated with their use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245:1066–73.

    Article  CAS  PubMed  Google Scholar 

  2. Cystic Fibrosis Foundation Patient Registry. 2013 Annual Data Report to the Center Directors. Cystic Fibrosis Foundation, Bethesda, Maryland. 2014. https://www.cff.org/2013_CFF_Annual_Data_Report_to_the_Center_Directors.pdf.

  3. Sexauer WP, Hadeh A, Ohman-Strickland PA, et al. Vitamin D deficiency is associated with pulmonary dysfunction in cystic fibrosis. J Cyst Fibros. 2015;14(4):497–506. This retrospective study suggests an association between vitamin D deficiency and pulmonary dysfunction.

  4. Lai HC, Kosorok MR, Laxova A, et al. Nutritional status of patients with cystic fibrosis with meconium ileus: a comparison with patients without meconium ileus and diagnosed early through neonatal screening. Pediatrics. 2000;105:53–61.

    Article  CAS  PubMed  Google Scholar 

  5. Corey M, McLaughlin FJ, Williams M, et al. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol. 1988;41:583–91.

    Article  CAS  PubMed  Google Scholar 

  6. Steinkamp G, Wiedemann B. Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. Thorax. 2002;57:596–601.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Stallings VA, Stark LJ, Robinson KA, et al. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc. 2008;108:832–9.

    Article  PubMed  Google Scholar 

  8. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr. 1998;132:589–95.

    Article  CAS  PubMed  Google Scholar 

  9. Peterson ML, Jacobs Jr DR, Milla CE. Longitudinal changes in growth parameters are correlated with changes in pulmonary function in children with cystic fibrosis. Pediatrics. 2003;112:588–92.

    Article  PubMed  Google Scholar 

  10. Dalzell AM, Shepherd RW, Dean B, et al. Nutritional rehabilitation in cystic fibrosis: a 5 year follow-up study. J Pediatr Gastroenterol Nutr. 1992;15:141–5.

    Article  CAS  PubMed  Google Scholar 

  11. Efrati O, Mei-Zahav M, Rivlin J, et al. Long term nutritional rehabilitation by gastrostomy in Israeli patients with cystic fibrosis: clinical outcome in advanced pulmonary disease. J Pediatr Gastroenterol Nutr. 2006;42:222–8.

    Article  PubMed  Google Scholar 

  12. Hirsch JA, Zhang SP, Rudnick MP, et al. Resting oxygen consumption and ventilation in cystic fibrosis. Pediatr Pulmonol. 1989;6:19–26.

    Article  CAS  PubMed  Google Scholar 

  13. Bell SC, Saunders MJ, Elborn JS, et al. Resting energy expenditure and oxygen cost of breathing in patients with cystic fibrosis. Thorax. 1996;51:126–31.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Shepherd RW, Greer RM, McNaughton SA, et al. Energy expenditure and the body cell mass in cystic fibrosis. Nutrition. 2001;17:22–5.

    Article  CAS  PubMed  Google Scholar 

  15. Fried MD, Durie PR, Tsui LC, et al. The cystic fibrosis gene and resting energy expenditure. J Pediatr. 1991;119:913–6.

    Article  CAS  PubMed  Google Scholar 

  16. Thomson MA, Wilmott RW, Wainwright C, et al. Resting energy expenditure, pulmonary inflammation, and genotype in the early course of cystic fibrosis. J Pediatr. 1996;129:367–73.

    Article  CAS  PubMed  Google Scholar 

  17. Naon H, Hack S, Shelton MT, et al. Resting energy expenditure. Evolution during antibiotic treatment for pulmonary exacerbation in cystic fibrosis. Chest. 1993;103:1819–25.

    Article  CAS  PubMed  Google Scholar 

  18. DiMagno EP, Go VL, Summerskill WH. Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency. N Engl J Med. 1973;288:813–5.

    Article  CAS  PubMed  Google Scholar 

  19. Kristidis P, Bozon D, Corey M, et al. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet. 1992;50:1178–84.

    CAS  PubMed Central  PubMed  Google Scholar 

  20. Layer P, Zinsmeister AR, DiMagno EP. Effects of decreasing intraluminal amylase activity on starch digestion and postprandial gastrointestinal function in humans. Gastroenterology. 1986;91:41–8.

    CAS  PubMed  Google Scholar 

  21. Wouthuyzen-Bakker M, Bodewes FA, Verkade HJ. Persistent fat malabsorption in cystic fibrosis; lessons from patients and mice. J Cyst Fibros. 2011;10:150–8.

    Article  CAS  PubMed  Google Scholar 

  22. Lavie M, Manovitz T, Vilozni D, et al. Long-term follow-up of distal intestinal obstruction syndrome in cystic fibrosis. World J Gastroenterol. 2015;21:318–25.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Dray X, Bienvenu T, Desmazes-Dufeu N, et al. Distal intestinal obstruction syndrome in adults with cystic fibrosis. Clin Gastroenterol Hepatol. 2004;2:498–503.

    Article  PubMed  Google Scholar 

  24. Borowitz D, Gelfond D. Intestinal complications of cystic fibrosis. Curr Opin Pulm Med. 2013;19:676–80. An in-depth review of the pathophysiology behind gastrointestinal complications of CF and highlighting recent relevant animal and human studies.

    Article  CAS  PubMed  Google Scholar 

  25. Morton JR, Ansari N, Glanville AR, et al. Distal intestinal obstruction syndrome (DIOS) in patients with cystic fibrosis after lung transplantation. J Gastrointest Surg. 2009;13:1448–53.

    Article  PubMed  Google Scholar 

  26. Fridge JL, Conrad C, Gerson L, et al. Risk factors for small bowel bacterial overgrowth in cystic fibrosis. J Pediatr Gastroenterol Nutr. 2007;44:212–8.

    Article  PubMed  Google Scholar 

  27. Ehre C, Ridley C, Thornton DJ. Cystic fibrosis: an inherited disease affecting mucin-producing organs. Int J Biochem Cell Biol. 2014;52:136–45. This paper discusses the potential causal relationship between altered cystic fibrosis transmembrane conductance regulator (CFTR) function and the production of mucus with abnormal biophysical properties in the intestine and lungs, highlighting what has been learned from cell cultures and animal models that mimic CF pathogenesis.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Munck A. Cystic fibrosis: evidence for gut inflammation. Int J Biochem Cell Biol. 2014;52:180–3.

    Article  CAS  PubMed  Google Scholar 

  29. Lisowska A, Pogorzelski A, Oracz G, et al. Oral antibiotic therapy improves fat absorption in cystic fibrosis patients with small intestine bacterial overgrowth. J Cyst Fibros. 2011;10:418–21.

    Article  CAS  PubMed  Google Scholar 

  30. Lewis C, Blackman SM, Nelson A, et al. Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex. Am J Respir Crit Care Med. 2015;191:194–200.

    Article  PubMed  Google Scholar 

  31. Marshall BC, Butler SM, Stoddard M, et al. Epidemiology of cystic fibrosis-related diabetes. J Pediatr. 2005;146:681–7.

    Article  CAS  PubMed  Google Scholar 

  32. Boyle MP. Adult cystic fibrosis. JAMA. 2007;298:1787–93.

    Article  CAS  PubMed  Google Scholar 

  33. Kelly A, Moran A. Update on cystic fibrosis-related diabetes. J Cyst Fibros. 2013;12:318–31.

    Article  PubMed  Google Scholar 

  34. Nousia-Arvanitakis S, Galli-Tsinopoulou A, Karamouzis M. Insulin improves clinical status of patients with cystic-fibrosis-related diabetes mellitus. Acta Paediatr. 2001;90:515–9.

    Article  CAS  PubMed  Google Scholar 

  35. Dobson L, Hattersley AT, Tiley S, et al. Clinical improvement in cystic fibrosis with early insulin treatment. Arch Dis Child. 2002;87:430–1.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. Hameed S, Morton JR, Field PI, et al. Once daily insulin detemir in cystic fibrosis with insulin deficiency. Arch Dis Child. 2012;97:464–7.

    Article  PubMed  Google Scholar 

  37. Brennan AL, Beynon J. Clinical updates in cystic fibrosis-related diabetes. Semin Respir Crit Care Med. 2015;36:236–50. This paper gives a comprehensive review of recent advances in the prevalence, clinical presentation and diagnosis of cystic fibrosis related diabetes including advances in treatment.

    Article  PubMed  Google Scholar 

  38. Rasouli N, Seggelke S, Gibbs J, et al. Cystic fibrosis-related diabetes in adults: inpatient management of 121 patients during 410 admissions. J Diabetes Sci Technol. 2012;6:1038–44.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Colombo C, Battezzati PM, Crosignani A, et al. Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology. 2002;36:1374–82.

    Article  PubMed  Google Scholar 

  40. Lamireau T, Monnereau S, Martin S, et al. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J Hepatol. 2004;41:920–5.

    Article  PubMed  Google Scholar 

  41. Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology. 1999;30:1151–8.

    Article  CAS  PubMed  Google Scholar 

  42. Bemeur C, Desjardins P, Butterworth RF. Role of nutrition in the management of hepatic encephalopathy in end-stage liver failure. J Nutr Metab. 2010;2010:489823.

    Article  PubMed Central  PubMed  Google Scholar 

  43. Colombo C. Liver disease in cystic fibrosis. Curr Opin Pulm Med. 2007;13:529–36.

    Article  PubMed  Google Scholar 

  44. Feranchak AP. Hepatobiliary complications of cystic fibrosis. Curr Gastroenterol Rep. 2004;6:231–9.

    Article  PubMed  Google Scholar 

  45. Culhane S, George C, Pearo B, et al. Malnutrition in cystic fibrosis: a review. Nutr Clin Pract. 2013;28:676–83.

    Article  PubMed  Google Scholar 

  46. Minicucci L, Lorini R, Giannattasio A, et al. Liver disease as risk factor for cystic fibrosis-related diabetes development. Acta Paediatr. 2007;96:736–9.

    Article  CAS  PubMed  Google Scholar 

  47. Crill CM, Wassil SK, Quiros-Tejeira RE. Liver disease and parenteral nutrition in an adolescent with cystic fibrosis. J Pediatr Pharmacol Ther. 2004;9:274–9.

    PubMed Central  PubMed  Google Scholar 

  48. Muller MJ, Bottcher J, Selberg O, et al. Hypermetabolism in clinically stable patients with liver cirrhosis. Am J Clin Nutr. 1999;69:1194–201.

    CAS  PubMed  Google Scholar 

  49. Corbett K, Kelleher S, Rowland M, et al. Cystic fibrosis-associated liver disease: a population-based study. J Pediatr. 2004;145:327–32.

    Article  PubMed  Google Scholar 

  50. Rowland M, Gallagher CG, O’Laoide R, et al. Outcome in cystic fibrosis liver disease. Am J Gastroenterol. 2011;106:104–9.

    Article  PubMed  Google Scholar 

  51. Colombo C, Costantini D, Rocchi A, et al. Effects of liver transplantation on the nutritional status of patients with cystic fibrosis. Transpl Int. 2005;18:246–55.

    Article  PubMed  Google Scholar 

  52. Sokol RJ, Durie PR. Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr. 1999;28 Suppl 1:S1–S13.

    Article  PubMed  Google Scholar 

  53. Debray D, Kelly D, Houwen R, et al. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros. 2011;10:S29–36.

    Article  PubMed  Google Scholar 

  54. Withers AL. Management issues for adolescents with cystic fibrosis. Pulm Med. 2012;2012:134132.

    Article  PubMed Central  PubMed  Google Scholar 

  55. Bregnballe V, Thastum M, Schiotz PO. Psychosocial problems in children with cystic fibrosis. Acta Paediatr. 2007;96:58–61.

    Article  CAS  PubMed  Google Scholar 

  56. Patterson JM, Wall M, Berge J, et al. Associations of psychosocial factors with health outcomes among youth with cystic fibrosis. Pediatr Pulmonol. 2009;44:46–53.

    Article  PubMed  Google Scholar 

  57. Tierney S. Body image and cystic fibrosis: a critical review. Body Image. 2012;9:12–9.

    Article  PubMed  Google Scholar 

  58. Lands LC, Iskandar M, Beaudoin N, et al. Dietary supplementation with pressurized whey in patients with cystic fibrosis. J Med Food. 2010;13:77–82.

    Article  CAS  PubMed  Google Scholar 

  59. Engelen MP, Com G, Wolfe RR, et al. Dietary essential amino acids are highly anabolic in pediatric patients with cystic fibrosis. J Cyst Fibros. 2013;12:445–53.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  60. Grey V, Mohammed SR, Smountas AA, et al. Improved glutathione status in young adult patients with cystic fibrosis supplemented with whey protein. J Cyst Fibros. 2003;2:195–8.

    Article  CAS  PubMed  Google Scholar 

  61. Roy CC, Darling P, Weber AM. A rational approach to meeting macro- and micronutrient needs in cystic fibrosis. J Pediatr Gastroenterol Nutr. 1984;3 Suppl 1:S154–62.

    Article  PubMed  Google Scholar 

  62. Cantin AM, White TB, Cross CE, et al. Antioxidants in cystic fibrosis. Conclusions from the CF antioxidant workshop, Bethesda, Maryland, November 11–12, 2003. Free Radic Biol Med. 2007;42:15–31.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  63. Dodge JA, Turck D. Cystic fibrosis: nutritional consequences and management. Best Pract Res Clin Gastroenterol. 2006;20:531–46.

    Article  CAS  PubMed  Google Scholar 

  64. Donovan Jr DS, Papadopoulos A, Staron RB, et al. Bone mass and vitamin D deficiency in adults with advanced cystic fibrosis lung disease. Am J Respir Crit Care Med. 1998;157:1892–9.

    Article  PubMed  Google Scholar 

  65. Vanstone MB, Egan ME, Zhang JH, et al. Association between serum 25-hydroxyvitamin D level and pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol. 2015;50:441–6.

    Article  PubMed  Google Scholar 

  66. Prasad AS. Clinical, biochemical and nutritional spectrum of zinc deficiency in human subjects: an update. Nutr Rev. 1983;41:197–208.

    Article  CAS  PubMed  Google Scholar 

  67. Sagel SD, Sontag MK, Anthony MM, et al. Effect of an antioxidant-rich multivitamin supplement in cystic fibrosis. J Cyst Fibros. 2011;10:31–6.

    Article  CAS  PubMed  Google Scholar 

  68. Britigan BE, Edeker BL. Pseudomonas and neutrophil products modify transferrin and lactoferrin to create conditions that favor hydroxyl radical formation. J Clin Invest. 1991;88:1092–102.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  69. FitzSimmons SC, Burkhart GA, Borowitz D, et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med. 1997;336:1283–9.

    Article  CAS  PubMed  Google Scholar 

  70. Borowitz D, Stevens C, Brettman LR, et al. International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients. J Cyst Fibros. 2011;10:443–52.

    Article  CAS  PubMed  Google Scholar 

  71. Borowitz DS, Grand RJ, Durie PR. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus Committee. J Pediatr. 1995;127:681–4.

    Article  CAS  PubMed  Google Scholar 

  72. Barraclough M, Taylor CJ. Twenty-four hour ambulatory gastric and duodenal pH profiles in cystic fibrosis: effect of duodenal hyperacidity on pancreatic enzyme function and fat absorption. J Pediatr Gastroenterol Nutr. 1996;23:45–50.

    Article  CAS  PubMed  Google Scholar 

  73. Proesmans M, De Boeck K. Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes. Eur J Pediatr. 2003;162:760–3.

    Article  CAS  PubMed  Google Scholar 

  74. Pencharz PB, Durie PR. Pathogenesis of malnutrition in cystic fibrosis, and its treatment. Clin Nutr. 2000;19:387–94.

    Article  CAS  PubMed  Google Scholar 

  75. Poustie VJ, Russell JE, Watling RM, et al. Oral protein energy supplements for children with cystic fibrosis: CALICO multicentre randomised controlled trial. BMJ. 2006;332:632–6.

    Article  PubMed Central  PubMed  Google Scholar 

  76. Smyth RL, Rayner O. Oral calorie supplements for cystic fibrosis. Cochrane Database Syst Rev. 2014;11:CD000406.

    PubMed  Google Scholar 

  77. Chinuck R, Dewar J, Baldwin DR, et al. Appetite stimulants for people with cystic fibrosis. Cochrane Database Syst Rev. 2014;7:CD008190.

    PubMed  Google Scholar 

  78. Epifanio M, Marostica PC, Mattiello R, et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. J Pediatr (Rio J). 2012;88:155–60.

    Article  Google Scholar 

  79. Homnick DN, Marks JH, Hare KL, et al. Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatr Pulmonol. 2005;40:251–6.

    Article  PubMed  Google Scholar 

  80. Marchand V, Baker SS, Stark TJ, et al. Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2000;31:264–9.

    Article  CAS  PubMed  Google Scholar 

  81. Eubanks V, Koppersmith N, Wooldridge N, et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. J Pediatr. 2002;140:439–44.

    Article  CAS  PubMed  Google Scholar 

  82. Anstead MI, Kuhn RJ, Martyn D, Craigmyle L, & Kanga JF. Dronabinol an effective and safe appetite stimulant in cystic fibrosis [abstract]. Pediatr Pulm Suppl. 2003;25:343.

  83. White H, Morton AM, Conway SP, et al. Enteral tube feeding in adults with cystic fibrosis; patient choice and impact on long term outcomes. J Cyst Fibros. 2013;12:616–22.

    Article  CAS  PubMed  Google Scholar 

  84. Erskine JM, Lingard CD, Sontag MK, et al. Enteral nutrition for patients with cystic fibrosis: comparison of a semi-elemental and nonelemental formula. J Pediatr. 1998;132:265–9.

    Article  CAS  PubMed  Google Scholar 

  85. Berry AJ. Pancreatic enzyme replacement therapy during pancreatic insufficiency. Nutr Clin Pract. 2014;29:312–21. This paper presents an in-depth review of pancreatic enzyme replacement therapy for CF related pancreatic insufficiency and discusses various limitations and recommended management.

  86. Shlieout G, Koerner A, Maffert M, et al. Administration of CREON(R) pancrelipase pellets via gastrostomy tube is feasible with no loss of gastric resistance or lipase activity: an in vitro study. Clin Drug Investig. 2011;31:e1–7.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Missale Solomon receives support through a Developing Innovative GastroEnterology Specialty Training (DIGEST) grant from the Cystic Fibrosis Foundation.

Karen Allen declares that she has no conflict of interest.

Mardeli Saire Mendoza declares that she has no conflict of interest.

Rodrigo Cavallazzi has received compensation from Cempra for participation in an advisory board meeting.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Drexel University, 219 N. Broad Street, 5th Floor, Philadelphia, PA, 19107, USA

    Missale Solomon

  2. Section of Pulmonary and Critical Care, University of Oklahoma Health Sciences Center, 920 Stanton L Young Blvd., Oklahoma City, OK, 73104, USA

    Karen Allen

  3. Section of Gastroenterology and Hepatology, Ochsner Medical Center, 1514 Jefferson Highway, New Orleans, LA, 70121, USA

    Mardeli Saire Mendoza

  4. Division of Pulmonary and Critical Care Medicine, University of Louisville, 550 S. Jackson Street, ACB, A3R27, Louisville, KY, 40202, USA

    Rodrigo Cavallazzi

Authors
  1. Missale Solomon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen Allen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mardeli Saire Mendoza
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rodrigo Cavallazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Missale Solomon.

Additional information

This article is part of the Topical Collection on Gastroenterology and Nutrition

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Solomon, M., Allen, K., Mendoza, M.S. et al. What Is the Role of Nutrition Therapy in the Management of the Adult Cystic Fibrosis Patient?. Curr Nutr Rep 4, 220–229 (2015). https://doi.org/10.1007/s13668-015-0136-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13668-015-0136-4

Keywords

Search

Navigation